CSL (CSLLY) Stock Price, News & Analysis

Company Overview

CSL Limited (OTCMKTS: CSLLY) is a global biotechnology company headquartered in Melbourne, Australia that develops, manufactures and delivers a range of plasma-derived and recombinant therapeutics, vaccines and related services. Its principal businesses include CSL Behring, which focuses on specialty biotherapies for bleeding disorders, immune deficiencies, hereditary angioedema and other serious conditions; Seqirus, an influenza vaccine company formed following CSL’s acquisition of Novartis’ influenza vaccine business; and CSL Plasma, a network of plasma collection centers that supplies the raw material for many of its therapies.

The company’s product portfolio spans immunoglobulins, clotting factor concentrates, albumin and other protein-based treatments used in the management of chronic and acute rare diseases, as well as seasonal and pandemic influenza vaccines. CSL invests in research and development to advance recombinant protein technologies, novel delivery formats and expanded indications for rare and serious conditions. Its integrated model—combining plasma collection, biologics manufacturing and global distribution—supports scale and supply reliability for clinically critical medicines.

Founded originally as Commonwealth Serum Laboratories, CSL has evolved from a national public health laboratory into a multinational biopharma enterprise with manufacturing, R&D and commercial operations across North America, Europe and the Asia–Pacific region. The company operates multiple manufacturing sites and maintains a broad global commercial footprint to serve hospital, specialist and public health customers worldwide.

CSL positions itself as a specialist provider to clinicians and public health agencies, emphasizing long-term investment in manufacturing capacity, plasma supply chains and scientific innovation. Its business model centers on continuity of supply for life‑sustaining therapies and vaccines, and on advancing treatments for rare and serious medical conditions through targeted research and strategic acquisitions.

Key Stats

• Today's Range: $18.50 to $19.20
• 50-Day Range: $16.35 to $25.40
• 52-Week Range: $16.01 to $44.86
• Volume: 371,663 shs
• Average Volume: 571,722 shs
• Market Capitalization: $36.40 billion
• P/E Ratio: N/A
• Dividend Yield: 3.11%
• Price Target: N/A
• Consensus Rating: Reduce

CSL Stock Analysis - MarketRank™

CSL scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Reduce

Consensus Rating

CSL has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

CSL has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for CSL are expected to remain at $1.57 per share in the coming year.

Price to Book Value per Share Ratio

CSL has a P/B Ratio of 1.72. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of CSL has been sold short.

Short Interest Ratio / Days to Cover

CSL has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CSL has recently increased by 161.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

CSL pays a meaningful dividend of 3.20%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

CSL does not have a long track record of dividend growth.

Dividend Sustainability

Based on earnings estimates, CSL will have a dividend payout ratio of 37.58% next year. This indicates that CSL will be able to sustain or increase its dividend.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CSL insiders have not sold or bought any company stock.

Percentage Held by Institutions

0.03% of the stock of CSL is held by institutions.

Company Calendar

• Today: 6/19/2026
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CSLLY
• CIK: 1274152
• Web: www.csl.com.au
• Phone: (139) 389-1911
• Fax: 61-3-9389-1434
• Employees: 29,904
• Year Founded: 1904

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.51
• Current Ratio: 2.57
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $15.56 billion
• Price / Sales: 2.34
• Cash Flow: $2.26 per share
• Price / Cash Flow: 8.42
• Book Value: $11.05 per share
• Price / Book: 1.72

Miscellaneous

• Outstanding Shares: 1,915,650,000
• Free Float: N/A
• Market Cap: $36.40 billion
• Optionable: Not Optionable
• Beta: 0.61